#China #Hangzhou #Venus Medtech #TAVR system #Venus-PowerX

Venus Medtech's Landmark Clinical Trial Success

Venus Medtech (Hangzhou) Inc., a leader in the field of transcatheter heart valve innovation, has recently announced the successful completion of patient recruitment for its pivotal clinical trial of the Venus-PowerX system. This groundbreaking device is recognized as the world’s first self-expanding, fully recoverable transcatheter aortic valve replacement (TAVR) system, a significant advancement in cardiology and structural heart disease treatment.

The completion of patient recruitment is a major milestone that propels the Venus-PowerX closer to market approvals in both China and Europe. The clinical study, known as PREVAILS, is designed as a prospective, multicenter, single-arm trial to rigorously assess the safety, efficacy, and performance of the Venus-PowerX system among patients suffering from severe aortic stenosis. The data gathered from this study is crucial, as it will support the simultaneous submissions for CE marking in Europe and regulatory approval from the Chinese National Medical Products Administration (NMPA).

Innovative Features of Venus-PowerX

What sets the Venus-PowerX apart from existing TAVR devices is its multitude of innovative technologies. Key features include:

• - 100% Recoverability: The device can be completely recovered after full deployment, addressing concerns about device permanence and complications associated with traditional valves.
• - Venus Endura™ Tissue: Constructed with anti-calcification treatment, ensuring longevity and functionality in the human body.
• - Cable-Controlled Deployment Mechanism: Allowing for precise placement and adaptability during the procedure.
• - Seadapt™ Adaptive Skirt: This unique design minimizes paravalvular leaks, enhancing the overall efficacy of the treatment.
• - V-Shaped Outlet Design: This feature optimizes blood flow, significantly contributing to the device's performance metrics.
• - Three Radiopaque Markers: Enhancing visualization during imaging, critical for procedural success.

The Venus-PowerX has already received regulatory approvals in several Latin American countries including Argentina, Chile, and Venezuela, marking its status as the first commercially available self-expanding TAVR system worldwide. Clinical data obtained from real-world applications in these regions offers a robust framework for expanding adoption in clinical settings. This strategic move aligns with Venus Medtech's goals to market effective solutions for structural heart diseases globally.

A Commitment to Patient Care

Mr. Ma Renzheng, the Chief Technology Officer at Venus Medtech, expressed confidence in the implications of this successful recruitment phase. He stated, "The successful completion of patient recruitment for the Venus-PowerX confirmation trial makes this device a significant addition to our TAVR product line. We are dedicated to offering patients suffering from severe aortic stenosis a more precise, safer, and manageable treatment option. Our aim is to evolve structural heart interventions from a 'partially manageable' level to an 'entirely manageable' stage at each procedural step."

As Venus Medtech innovates and develops its product offerings, the company remains poised at the forefront of heart disease treatment methodologies. With global R&D facilities located in China, the United States, and Israel, Venus Medtech continues to drive forward in the quest to enhance the efficacy of treatments for life-threatening cardiac conditions. This phase not only underlines the company's commitment to improving patient outcomes but also their ambition to become a leader on the global stage in the structural heart disease space.

Keep an eye on this revolutionary technology as Venus Medtech moves closer to realizing its potential—both for patients and for the medical community. The future of heart valve replacement is indeed evolving, thanks to the relentless pursuit of innovation in the healthcare sector.